LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024.

Key highlights from this period include:

• Pivotal clinical study of SPONTAN® fully recruited and completed dosing of all participants.
• SPONTAN achieved key manufacturing validation and first commercial batch production.
• SPONTAN is designed to be a world-first, fast-acting, on-demand Nasal Spray treatment for Erectile Dysfunction (ED).

LTR Pharma Chairman, Lee Rodne, said:

“We are pleased to share that LTR Pharma has made significant strides towards bringing SPONTAN to market this quarter. We completed the dosing phase of the pivotal study and met critical FDA requirements for manufacturing validation. We remain on track with a strong cash position to achieve our milestones and revolutionise the global erectile dysfunction treatment landscape.”

Click here to read the ASX release.